RxDoctor Payments Data

Talin Khachatoor Sarkissian, OD

Optometrist · Pasadena, CANPI 1497391932

Payments from drug & device makers

$3,950in general payments, 2019–2025

Across 159 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$2K
  • Mallinckrodt Hospital Products Inc.$662
  • Tarsus Pharmaceuticals, Inc.$273
  • Alcon$261
  • Oyster Point Pharma, Inc.$253
  • Astellas Pharma US Inc$147
  • plus $596 from 9 others

What the payments were for

  • Food & beverage$3,85097%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,950 in reported general payments places this provider in the 90th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$1,944
Medicare patients
18
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine194$194,072
Cyclosporine158$80,280
XiidraLifitegrast54$66,879
LumiganBimatoprost118$61,837
CequaCyclosporine57$58,412
RocklatanNetarsudil Mesylat/Latanoprost49$19,098
MieboPerfluorohexyloctane/Pf24$17,511
Alphagan PBrimonidine Tartrate59$17,220
RhopressaNetarsudil Mesylate41$15,579
Latanoprost1,100$13,093
VyzultaLatanoprostene Bunod18$10,685
Brimonidine Tartrate269$10,194
TyrvayaVarenicline Tartrate12$7,656
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol49$6,175
CombiganBrimonidine Tartrate/Timolol21$6,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$16$279,294392 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$72$95,07596 claims
Sun Pharmaceutical Industries Inc.Cequa$1,758$58,41257 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$80$34,67790 claims
Oyster Point Pharma, Inc.Tyrvaya$253$7,65612 claims
AlconSimbrinza$261$4,89725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,778 optometrist providers in California.

Other optometrist in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →